AVIR vs AVXL

Atea Pharmaceuticals, Inc. vs Anavex Life Sciences Corp. — Valuation Comparison 2026

AVIR

Biotechnology
Atea Pharmaceuticals, Inc.
Quality
4.2
out of 10
Value Trap
18
SAFE
Price
$4.73
Last close
Models
8/13
Active
VS

AVXL

Biotechnology
Anavex Life Sciences Corp.
Quality
4.3
out of 10
Value Trap
6
SAFE
Price
$2.94
Last close
Models
10/13
Active

Model-by-Model Comparison

ModelType AVIR Fair ValueAVIR Upside AVXL Fair ValueAVXL Upside
Bayesian DCF Intrinsic $1.47 -68.9% $1.56 -46.8%
Earnings Power Value Intrinsic $1.52 -54.1%
EROIC Spread Intrinsic $•••.•• ••.•% $•••.•• ••.•%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
Markov DDM Intrinsic $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.59 -89.4% $0.37 -88.8%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for AVIR vs AVXL — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

AVIR vs AVXL — Which Stock Is More Undervalued?

AVXL scores higher with a 4.3/10 quality rating vs AVIR's 4.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Atea Pharmaceuticals, Inc. (AVIR) and Anavex Life Sciences Corp. (AVXL) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

AVIR currently trades at $4.73 with a QOC of 4.2/10, while AVXL trades at $2.94 with a QOC of 4.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).